Industry Roundup: Thermo Fisher Scales Orbitrap Platform Across Research, Biopharma, and Environmental Testing at ASMS 2026

Thermo Fisher Scientific used the 2026 American Society for Mass Spectrometry (ASMS) conference to unveil an expansion of its Orbitrap mass spectrometry portfolio, introducing three new instrument platforms, a suite of AI-enabled software tools and end-to-end workflows targeting proteomics research, biopharmaceutical development, and regulated environmental and food safety testing.¹

The announcements reflect a strategic push to extend the resolving power and confident quantitation that have made Orbitrap technology a workhorse in discovery research into settings where throughput, regulatory compliance, and cost-per-sample matter as much as raw performance.

A More Versatile Tribrid for Complex Biology

At the research end of the portfolio, the Orbitrap Tribrid Apex MS is positioned as the company's highest-performing Tribrid platform to date. The system integrates three mass analyzers—ion trap, Orbitrap, and a quadrupole—on a single instrument and adds a new infrared laser fragmentation option alongside the company's Direct Mass Technology Mode for intact-mass and top-down analyses. According to the press release, the combination is intended to reduce the instrument-switching overhead that currently fragments discovery proteomics workflows across multiple platforms.¹

Supporting the hardware, Thermo Fisher announced the acquisition of two software firms: MSAID, which brings machine-learning-driven peptide identification and AI-assisted spectral interpretation, and Proteinaceous, a specialist in bioinformatics for top-down and native mass spectrometry. The company also released Proteoform Studio, a new software environment that connects Direct Mass Technology acquisition directly to reporting, and updated Proteome Discoverer to version 3.4, expanding workflow consolidation and data coverage in a single environment.

Reducing Tradeoffs in Drug Development

For pharmaceutical laboratories, the central announcement was the Orbitrap Excedion MS, described as purpose-built to address performance tradeoffs common in drug metabolism and oligonucleotide analysis. The instrument features enhanced dynamic range (eDR) technology, which Thermo Fisher claims enables detection of three to five times more compounds in a single injection of a complex matrix compared with standard configurations. Crucially, the platform supports a field upgrade path to the Excedion Pro configuration, allowing laboratories to expand analytical capability without full instrument replacement, a consideration that carries real weight in environments where method revalidation is expensive.

Accompanying the Excedion, Thermo Fisher introduced the Vanquish Amplify ultrahigh-performance liquid chromatography (UHPLC) system, featuring a metal-free inert sample path intended to minimize adsorption of sensitive oligonucleotides and biologics, and SurePac RP MDi columns purpose-built for mRNA, oligonucleotide, and protein therapeutics. The SMART Digest OligoSelect Kit rounds out the sample preparation side with a single-tube workflow for oligonucleotide bioanalysis. BioPharma Finder 5.5 software closes the loop on the top-down data-processing side, with faster deconvolution of complex spectra from the latest instrument platforms.

For QA/QC and regulated bioanalysis, the TSQ Certis triple quadrupole MS was showcased with claimed improvements of 15% faster sample throughput and a more than twofold increase in maintenance intervals on complex matrices such as plasma.

High-Resolution Screening for Dioxins, PFAS, and Emerging Contaminants

In the applied testing market, Thermo Fisher introduced the Orbitrap Exploris GC S MS, a high-resolution gas chromatography–mass spectrometry (GC–MS) platform targeting dioxin and persistent organic pollutant analysis for environmental and food safety laboratories. The system delivers more than twice the resolving power of many sector-based instruments currently in regulatory use, with a single platform handling both established contaminant panels and suspect screening for emerging compounds.

Complementing the GC platform, the Orbitrap Exploris EFOX Mass Detector addresses high-resolution liquid chromatography (LC)–MS screening of PFAS, pesticides, and related analytes, while the TSQ Altis Plus EFOX triple quadrupole handles confirmatory quantitation in the same workflow.

Taken together, Thermo Fisher believes that their ASMS 2026 announcements represent the company’s most extensive simultaneous Orbitrap product launch in recent memory—one aimed squarely at laboratories facing the dual pressure of expanding analyte lists and tightening timelines for defensible results.

For more information, please visit www.thermofisher.com.

Reference

1. Thermo Fisher Scientific Expands Orbitrap Innovation Across Research, Biopharma and Applied Testing at ASMS 2026. Thermo Fisher press release (accessed 2026-05-28).